Keystone, which wouldn't be complete until 2016, long after Crimea has quieted down, would move only 830,000 barrels of oil a day—less than 1 percent of world demand
DIsney's MyMagic+ technology may make a trip to Disney World more magical—or creep customers out
Russia's aggression in Ukraine is a test of American influence—and a reminder of its limits
Via embed code, Getty now allows anyone to display an image on blogs or Facebook pages without paying a licensing fee
McDonald's, Amgen, and DuPont make generous contributions; Wynn Resorts is stingier
Samuel Achilefu and his team at Washington University can more easily catch stray cancer cells
Taking criticism is hard, but you gotta do it
European MBA programs compete with top-tier U.S. schools for the best students at home and abroad
Organizations offer special training for senior entrepreneurs
King of Prussia, Pa.
Founders: Dr. Robert Lefkowitz and Dr. Howard Rockman
VC Investment over the last four quarters: $26.1 million
Trevena, founded in January 2008, is a drug discovery company developing pharmaceuticals that target what are known as G-protein coupled receptors. Such drugs make up more than 40% of marketed drugs today, according to Trevena. The company's drug discovery platform is based on research from Duke University Medical Center, including that of founder and National Medal of Science winner Robert Lefkowitz.
Key to startup success: "We've been able to generate the strong investor support for this idea [because] the technology and the opportunity here is very, very unique, and the possibility of unlocking new areas of biology is so significantly different from what's currently out there."